DiscoverPETRI DISH PERSPECTIVES
PETRI DISH PERSPECTIVES
Claim Ownership

PETRI DISH PERSPECTIVES

Author: Manead Khin

Subscribed: 1Played: 9
Share

Description

Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎

Stream new episodes every THURSDAY!


https://linktr.ee/maneadkhin


#biotech #pharma #healthcare #podcast #petridishperspectives

94 Episodes
Reverse
Send us Fan Mail After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often after years and millions of dollars. As co-founder and Chief Business Officer of Deep Origin, she helps build computational models that span the quantum mechanical to the whole human body. The goal is to predict drug safety before a molecule reaches an animal or a patient. Deep O...
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years posting anonymously on biotech X as “Professor Oak,” built a reputation in the crossover investing world without ever revealing his name, and then founded Mithril with Atlas Venture, one full-time employee (himself), and Claude running operations across 11 external laboratories. ...
Send us Fan Mail After a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the company describes as the first epigenetics-based clinical test for heart disease driven by AI, then took the company public on Nasdaq in 2022. Since then, it has earned a dedicated AMA CPT code for its PrecisionCHD test, won a Vizient innovative technology contract, and launched ...
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled the GLP-1 race, and M&A activity that shows Big Pharma is quietly pivoting away from oncology toward rare disease, pain, and RNA therapeutics. The FDA approved dostarlimab in locally advanced rectal cancer, tucatinib in HER2-positive breast cancer, and talazoparib plus enzalutam...
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown into NorthShore University HealthSystem, expanded through a 2022 merger with Edward-Elmhurst Health, and rebranded as Endeavor Health in December 2023, this is a system that has been quietly becoming one of the largest in the state. We break down Endeavor’s origins, its nine-hos...
loading
Comments